Tumor growth was monitored by μCT or caliper measurements, and immunohistochemistry (PCNA) was used to assess proliferation.<h4>Results</h4>In vitro, adagrasib reduced AMD1 levels, and SAM486A synergistically enhanced its antiproliferative effects, particularly in KRAS<sup>G12C</sup>-mutant cell lines, with minimal effects on KRAS-wild-type cells. Here, KRAS is linked to neoplasm.